PIQ
PROTEOMICS INTERNATIONAL LABORATORIES LTD
$0.1250
▲ +8.70%
Market cap
$21M
Turnover
$9,830
Last price
$0.1250
Day change
+8.70%
Announcements
10
Range, past year
Open 0.365 · Low 0.096 · Now 0.125 · High 0.860
Open PIQ in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
PIQ momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
23/100
Wyckoff phase
Downtrend22d
Trend stage
Breakdown
1 Day
+8.7%
1 Week
-7.4%
1 Month
-19.4%
1 Year
-64.3%
RSI
40
Avg daily range
7.7%
PROTEOMICS INTERNATIONAL LABORATORIES LTD scores 23 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 22 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -43.9%
- High volatility (ATR 7.7%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsPIQ announcements
Recent price-sensitive releases.
- 2026-09-14 PromarkerD and PromarkerEso Commercial Rollout Update Progress Report
- 2026-08-31 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-13 Australian patent for PromarkerEndo Progress Report
- 2026-07-27 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-22 Proteomics signs national distribution deal with Healius
- 2026-07-08 US patent secured for PromarkerEndo
- 2026-05-07 Response to ASX Price Query
More Health Care stocks
Most traded in the same sector.